South Sudan & Gilead Sciences

South Sudan: South Sudan is identified as a high-risk neighboring country due to its proximity to the outbreak's epicenter and intense population movement, necessitating reinforced cross-border surveillance.

Gilead Sciences: Gilead Sciences is a key partner in the urgent high-level coordination meeting convened by United States — Centers for Disease Control and Prevention, potentially involved in assessing medical countermeasures for the Ebola outbreak.

South Sudan: South Sudan>>> is identified as a country at risk of Ebola spread due to its proximity and population movement with the affected regions in the Democratic Republic of the Congo>>> and Uganda>>>.

Gilead Sciences: Gilead Sciences' antiviral drug remdesivir and experimental drug obeldesivir are being prioritized for clinical trials to treat or prevent the Bundibugyo ebolavirus, indicating its significant role in potential therapies.

South Sudan: Neighboring country at risk of importation; no confirmed cases reported.

Gilead Sciences: Supplying remdesivir for clinical trials; potential positive impact if treatment proves effective.

South Sudan: South Sudan is one of the countries whose nationals face travel bans from the US due to the Ebola outbreak in the Democratic Republic of the Congo.

Gilead Sciences: Gilead Sciences' experimental oral COVID antiviral drug, Obeldesivir, is being considered for use as a preventative treatment for Ebola contacts, under strict protocol.

South Sudan: South Sudan is among the nations from which the United States has imposed travel restrictions due to the Ebola outbreak.

Gilead Sciences: Gilead Sciences' antiviral remdesivir is mentioned as a potential treatment to be used at the quarantine facility, indicating its role in the medical response to Ebola.

South Sudan: Borders Ituri province, at risk of imported cases.

Gilead Sciences: Developed obeldesivir, the antiviral being tested in the EBO-PEP trial.